Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
368
resultados
Última actualización
02/11/2026 [10:35:00]
Resultados 275 a 300 de 368
Resumen de: CN122319365A
Disclosed is a method for quantifying plasmalogen, which comprises: a measurement sample preparation step for obtaining a measurement sample by mixing a sample containing a protein and plasmalogen with a Schiff reagent; a control sample preparation step of mixing the test sample with the solvent of the Schiff reagent to obtain a control sample; a measurement step for measuring the degree of the first optical property of the measurement sample and the degree of the optical property of the control sample after the reaction of an aldehyde generated from the vinyl ether bond of the plasmalogen and the Schiff reagent; and a determination step for determining the concentration of the plasmalogen in the sample by comparing the degree of correction, which is obtained by correcting the degree of the first optical property using the degree of the optical property of the control sample, with the degree of the second optical property of a standard sample containing a Schiff reagent and a plasmalogen having a known concentration, and determining the concentration of the plasmalogen in the sample. The degree of the second optical property is the degree of reaction of the Schiff reagent with the aldehyde generated by the vinyl ether linkage of the plasmalogen.
Resumen de: CN122726299A
0001 本发明公开了一种抗人Aβ1‑40和Aβ1‑42的单克隆抗体和基于其的产品以及应用，属于单克隆抗体技术领域。所述抗体包括轻链和重链，轻链属于kappa型，重链属于IgG2b型；其轻链可变区的3个互补决定区的氨基酸序列分别如SEQ ID No.1、2、3所示；重链可变区的3个互补决定区的氨基酸序列分别如SEQ ID No.9、10、11所示。该抗体经由化学合成的人Aβ1‑20短肽偶联KLH作为抗原免疫小鼠后，经融合和数次克隆化筛选获得，能同时高效特异性识别人Aβ1‑40和Aβ1‑42，不结合BSA、KLH‑p‑Tau217、NFL等无关蛋白，平衡解离常数达皮摩尔级（Kd ≈ 51 pM），可用于人Aβ1‑40和Aβ1‑42的定量检测与体外诊断试剂盒开发，同时在Aβ相关疾病的抗体治疗中具有应用潜力。
Resumen de: CN122726282A
本发明涉及生物医学领域，具体而言，涉及一种β‑淀粉样寡聚物的检测方法及分子探针。该分子探针的氨基酸序列中包括免疫球蛋白样受体LilrB2胞外结构域的D1D2蛋白氨基酸片段，β‑淀粉样寡聚物包括散发性阿尔兹海默症β‑淀粉样寡聚物突变体，还包括家族性阿尔兹海默症β‑淀粉样寡聚物突变体。该检测方法可对阿尔茨海默病早期阶段的精准诊断，具有广谱识别能力，对Aβ寡聚物具有良好的选择性和特异性，可对脑组织、脑脊液和血液等样本进行体外检测，实现无创早期诊断，具有广阔的临床转化前景。
Resumen de: WO2025080894A1
In one aspect, the present disclosure provides a method of detecting a presence or absence of a biomarker for a disease in the sample, wherein the biomarker comprises: a) a complex of physiologically active target macromolecules or a fragment or portion thereof and target macromolecules that are not physiologically active; b) a conformation of the physiologically active macromolecules or fragment thereof when the physiologically active target macromolecules or the fragment or portion thereof is a complex with a non- physiologically active target macromolecule; c) the conformation of physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; d) the conformation of non-physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; or e) a combination of a), b), c), d) and/or e).
Resumen de: CN122726026A
0001 本申请公开了一种化合物及其制备方法、作为探针的应用，属于探针领域。所述化合物的结构式为式I所示
该探针不仅具备淀粉样蛋白的靶向能力，能够特异性结合淀粉样蛋白，还能够在硼酸存在的条件下实现对淀粉样蛋白的选择性标记。可用于神经退行性疾病模型等多种淀粉样蛋白相关疾病中沉积蛋白的组分鉴定。
Resumen de: CN122731161A
0001 本发明提供了一种检测褪黑素的体外微针贴片及其制备方法和应用，涉及生物医用材料和器械技术领域。本发明检测褪黑素的体外微针贴片的制备方法，包括以下步骤：固体微针贴片用2~100μg/mL兔抗人褪黑素IgG溶液进行蛋白包被，得检测褪黑素的体外微针贴片；所述固体微针贴片先经表面亲水修饰或不经表面亲水修饰，所述表面亲水修饰包括等离子处理。本发明制备方法能够使得体外微针贴片定量检测微量的、特定的褪黑素蛋白，具有高灵敏度、高准确性。
Resumen de: CN122731146A
本发明公开了一种基于白质骨架连续谱坐标的α‑突触核蛋白病定位方法。该方法包括建模阶段与应用阶段：建模阶段将多壳层扩散磁共振的多个微结构参数统一投射至白质骨架空间，以预设的健康‑前驱‑临床连续谱顺序为约束，结合多参数排他式筛选规则识别阶段敏感白质簇，并构建以健康组与临床期组中心向量连线为连续谱主轴的参考轴及坐标映射规则；应用阶段将待评估对象经相同处理后的特征投影至该主轴，输出连续谱坐标值、阶段偏移量及阶段邻近度。本发明能够在单次横断面扫描下实现个体在疾病连续谱中的定量定位，克服了现有技术依赖纵向数据或离散状态判定的局限，可以广泛应用于α‑突触核蛋白病的早期识别与个体化评估。
Resumen de: CN122731053A
本发明公开了一种多功能的多模态串联质谱标签及其在化学蛋白质组学定量中的应用。所述标签包含亲和富集模块、可断裂连接模块和等量异位标签模块，其中等量异位标签模块整合有报告基团、质量平衡基团和生物正交反应把手。该标签具有全新的等量异位标签骨架，不含氨基反应活性基团，避免了赖氨酸侧链误标记；末端炔基可通过一步点击化学反应与叠氮标记的肽段连接，实现化学蛋白质组学流程中富集、释放和定量功能的一体化安装。实验表明，本发明标签在二级质谱中可稳定释放报告离子，报告离子信号强度比与标记肽段混合比例高度一致，在10倍差异范围内定量准确。本发明简化了化学蛋白质组学定量操作，减少样本损失，提高了定量的准确性和便捷性。
Resumen de: CN122721423A
0001 本发明属于生物医药技术领域，公开了维卡格雷或其药用盐在制备环鸟腺苷合成酶（cGAS）乙酰化抑制剂以及在制备用于治疗自身免疫性疾病和神经退行性疾病的药物中的用途。
Resumen de: US20260265365A1
The present disclosure relates to anti-interleukin-11 (IL-11) antibodies and antigen-binding fragments thereof including their use in the treatment or prevention of an IL-11 (interleukin 11) pathway disease or disorder.
Resumen de: US20260264076A1
0000 A multiplexed capillary-flow immunoassay device configured for the simultaneous detection of multiple analytes, specifically, a testing assembly including a detection area, a fluid inlet, and a microfluidic network including at least two microfluidic pathways directed to distinct detection areas each configured to detect a different analyte.
Resumen de: US20260266724A1
An apparatus and method for identifying a protein or proteins in a sample of a biofluid. The identification is based on illuminating the sample with ultraviolet radiation and detecting and analyzing the resulting fluorescence. A trained model may be used to determine a protein responsible for a spectra detected from the illumination of the sample.
Resumen de: US20260266848A1
0000 Disclosed herein are compositions, kits, and methods for identifying protein, miRNA, or metabolite biomarkers for dystonia, for treating a subject having a dystonia, for selecting a subject for a clinical trial, for selecting a therapeutic agent, for treatment of dystonia in a subject, for classifying a subject having dystonia, and for predicting responsiveness to a dystonia treatment.
Resumen de: AU2025223493A1
The present disclosure provides nucleic acids, compositions, and methods of preventing or treating neurodegenerative disease in a subject comprising administering to the subject an agent that targets CHMP2B. In some embodiments the present disclosure provides a method of preventing or decreasing nuclear accumulation of CHMP7 in a cell comprising contacting the cell with an agent that targets expression of CHMP2B in the cell.
Resumen de: AU2024395871A1
The present disclosure provides methods for simultaneously identifying dynamic and disease-associated RNA binding protein (RBP)-RNA interaction (PRI) sites at single nucleotide resolution across the entire transcriptome. The methods disclosed herein recapitulates PRI profiles obtained with several distinct conventional PRI methods in a single assay at efficiencies that are improved by orders of magnitude, and permit the identification of the specific RBP bound at a PRI.
Resumen de: WO2026188004A1
Provided are methods for determining the risk or monitoring the progression of Alzheimer's disease in a subject using expression levels of one or more circRNAs. Also provided are methods for treating a subject identified as having or at risk for Alzheimer's disease.
Resumen de: WO2026187868A1
The present disclosure provides specific anti-ac-tauK174, anti-ac-tauK274, and ac-tauK353 antibodies, or antigen-binding fragments thereof, and methods of their use in diagnosing, differentiating, targeting, staging, prognosing, and/or treating Alzheimer's Disease and related tauopathies, including traumatic brain injury. Methods of identifying a subject having early Alzheimer's Disease and related tauopathies are also provided, the methods comprising detecting proteins using at least one anti-ac-tauK174 antibody, at least one anti-ac-tauK274 antibody, and/or at least one anti-ac-tauK353 antibody. In some embodiments, the subject is ApoE4-positive.
Resumen de: US20260265322A1
0000 Disclosed herein include polynucleotides, expression vectors and compositions enabling expression of a self-assembling proteopathic fusion protein comprising a self-assembling domain fused to a proteopathic polypeptide associated with a proteinopathy. The self-assembling proteopathic fusion protein is capable of forming intracellular protein aggregates that enable robust recapitulation of disease pathology. Provided herein also include methods of using the self-assembling systems disclosed herein to induce proteinopathies (e.g., neurodegenerative diseases) and to screen therapeutic compounds for the treatment of proteinopathies.
Resumen de: WO2026187918A1
Provided herein are systems, devices and methods relating to the diagnosis of traumatic brain injury. A mobile application uses a smartphone camera and an on-device artificial intelligence model to read lateral flow assay test strips and produce a concussion diagnostic result. The application determines whether a concussion biomarker is present in a sample and, when present, calculates a numeric intensity score that reflects the strength of the biomarker signal. Before displaying any result, the application automatically checks the image and test for a set of quality and validity conditions and, if any problem is found, tells the user specifically what went wrong and how to correct it. The application guides users through the entire testing process with a step-by-step interface designed to be usable without clinical training, stores all completed results on the device for longitudinal review, and can optionally receive data from a paired hardware lateral flow assay reader.
Resumen de: US20260266800A1
Systems, devices, and methods herein may include a system for monitoring bodily fluid from a patient. In some embodiments, the system may be configured to collect bodily fluid samples from a patient periodically over time to determine a baseline bodily fluid composition. In some embodiments, the system may use spectrophotometry to determine the baseline bodily fluid composition for the patient. The system may be configured to compare a bodily fluid sample to the baseline bodily fluid composition to detect detecting changes in one or more characteristics of the bodily fluid sample (e.g., composition, absorption spectrum, etc.) from the baseline. Changes in the bodily fluid sample characteristics may be used to predict and/or detect abnormalities or infection for individualized diagnosis.
Resumen de: WO2026187110A1
The present invention relates to a method for customized diagnosis of patients with acyl coenzyme A overproduction and screening for therapeutic agents for acyl coenzyme A overproduction-associated diseases by using a metabolite having a nucleophilic amine group. The present invention provides a method capable of indirectly identifying the degree of acyl coenzyme A overproduction by measuring an acyl-product generated upon ingestion of a metabolite having a nucleophilic amine group, and thus enables customized diagnosis of patients with acyl coenzyme A overproduction and screening for customized therapeutic agents for diseases caused by acyl coenzyme A overproduction.
Resumen de: WO2026185475A1
The invention relates to a method for measuring production and/or reduction of the concentration of a chemical species from a microbiota sample of a subject, the method comprising: - preparing a solution to be analysed by adding a buffer solution to a microbiota sample of a subject; - measuring, with a measuring device, a concentration of the chemical species in the solution to be analysed at an initial time in order to obtain a reference measurement of the concentration of the chemical species in the sample at the initial time; then - carrying out multiple successive measurements of the concentration of the chemical species in the solution to be analysed during a determined period in order to establish a data sequence representing the production and/or the reduction of the chemical species in the solution to be analysed over time, wherein the chemical species is chosen from NO and NO 2 -.
Resumen de: US20260266849A1
0000 Methods for serial amplification of Tau filaments and Tau assemblies include contacting monomeric Tau protein with Tau seed material under conditions permissive for seed-dependent fibril or assembly growth to produce amplified Tau filaments or assemblies, processing at least a portion of the amplified material to generate Tau seed material for further amplification, and repeating the contacting and processing steps to produce serially amplified Tau filaments or assemblies, where the monomeric Tau includes one or more Tau isoforms, variants, fragments, or modified forms. In some embodiments, Tau seed material is obtained from a biological sample associated with a Tauopathy. The methods further include characterizing amplified Tau filaments or assemblies or using the serial amplification process to identify compounds that modulate Tau assembly propagation by comparing propagation characteristics in the presence and absence of a test compound.
Resumen de: WO2026188078A1
The invention relates to quantitative blood-based protein biomarkers and computational methods for detecting and monitoring inner ear disorders and hearing loss. Proteins identified in plasma and extracellular vesicles following noise exposure, ototoxic drug administration, or age-related degeneration are quantified using mass spectrometry, aptamer-based array assays, or immunoassays. Inner ear disorder is identified based on defined fold-change thresholds or multi-biomarker panel performance achieving an AUC of at least 0.75. The invention further provides computer-implemented classification methods and diagnostic kits for early detection and therapeutic monitoring of inner ear disorders.
Nº publicación: US20260266814A1 10/09/2026
Solicitante:
WISCONSIN ALUMNI RES FOUNDATION [US]
Wisconsin Alumni Research Foundation
Resumen de: US20260266814A1
0000 Methods and kits for selectively separating biomolecules in complex samples, such as in blood serum, plasma, and other biological fluids. Metal-organic frameworks (MOFs) are formed around selected biomolecules in a mixture during an in-situ growth process, thereby allowing these biomolecules to be separated more easily from molecules that are not encapsulated by the MOFs. One aspect of the invention separates high-abundance proteins from a biological fluid to enhance the detection and characterization of lower-abundance or harder to detect proteins. This allows the lower-abundance or harder to detect proteins to be more easily detected and accurately analyzed, for example, by mass spectrometry. This is particularly useful in blood samples that contain highly-abundant plasma proteins that interfere with the mass spectrometry analysis of lower-abundant proteins and and protein biomarkers.
BOPI
Sede Electrónica
